Diplomat Acquires Focus Rx Specialty & Infusion Pharmacy

Buyer: Diplomat Pharmacy (DPLO)
Seller: Focus Rx
Date / Year: September 11, 2017
Sector: Specialty Pharmacy and INfusion

FLINT, Mich., Sept. 11, 2017 /PRNewswire/ — Diplomat Pharmacy, Inc. (NYSE: DPLO), has completed its acquisition of Focus Rx Pharmacy Services Inc., a specialty and infusion pharmacy with two locations in New York state.

Focus Rx is a customer-focused health care partner that provides home infusion and specialty prescription management services. This acquisition bolsters Diplomat’s offering of extensive solutions to meet growing demand for infusion therapies.

“This partnership opens growth opportunities, especially in the key markets of New York and New Jersey,” said Phil Rielly, Diplomat vice president and president of Diplomat Specialty Infusion Group. “Focus Rx brings over 15 regional and national payor contracts, boosting Diplomat’s prescription and payor access.”

Diplomat’s specialty infusion services are built on the combined experience of experts in a range of areas and fully dedicated to meeting the specialized needs of individuals living with chronic conditions including alpha-1 antitrypsin deficiency, hemophilia, hereditary angioedema, immune deficiencies, nutritional deficiencies, and von Willebrand disease. The Focus Rx nutrition deficiency business will complement ThriveRx, the nutrition division of Diplomat Specialty Infusion Group—providing significant growth in the New York market.

“As a specialty infusion provider in today’s rapidly evolving health care environment, we are excited to partner with Diplomat to enhance the delivery of comprehensive and personalized services to our patients,” said Lou Puleo, CEO of Focus Rx. “Our efforts improve patient results, as well as the clinical, operational, and financial well-being of our partners,” Puleo said. “Diplomat will further our commitment, enabling us to deliver integrated health care services to new and existing consumers and advancing our strong clinical expertise.”  Focus Rx is expected to generate approximately $47 million in revenue and $3 million in adjusted EBITDA for the full year 2017.

About Diplomat

Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

About Focus Rx

Focus Rx is a health care partner that provides home infusion and specialty prescription management services. The company partners with hospitals, specialty practices, and clinics to deliver comprehensive and personalized services. Focus Rx improves patient outcomes, as well as its partners’ clinical, operational, and financial well-being. For more information, visit myfocusrx.com.

Contact Us

Paragon Ventures - CONFIDENTIAL CONTACT REQUEST (Market Pulse)
Sending

NSM Acquires Rehab Division of Dynamic Healthcare Services
Owens & Minor pays $710mm for Halyard surgical supply business